Cincinnati Children’s prominent national role in vaccine research and development will continue under the new, federally-funded Infectious Diseases Clinical Research Consortium.
This clinical trials network, announced Dec. 19, 2019, by the National Institute of Allergy and Infectious Diseases (NIAID), encompasses nine long-standing Vaccine and Treatment Evaluation Units (VTEUs) and creates a new consortium leadership group.
NIAID intends to provide approximately $29 million per year for seven years for the VTEU program and its companion leadership group. Cincinnati Children’s will receive a base award of $4.2 million over seven years with additional funds to be awarded per project.
The VTEU program was established in 1962. Cincinnati Children’s has been a participating center since 1994.
“This grant places Cincinnati in the forefront of our national effort to combat infectious diseases and offers us the opportunity to be the leader in developing and testing vaccines,” says Robert Frenck, MD, a physician in the Division of Infectious Diseases and principal investigator for the grant. “Vaccines are the single most cost-effective strategy we have to combat infectious diseases, and the VTEU network is a critical component of the effort to prevent and treat infectious diseases that threaten the health and lives of millions of people in the U.S. and throughout the world.”
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.